Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfCS102 Malaria Vaccine Efficacy Trial
NCT01031524Phase 2Completed
- Sponsor
- Swiss Tropical and Public Health Institute
- Start
- Mar 2004
- Primary completion
- Jul 2004
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PfCS102 in Plasmodium falciparum malaria (2 arms), sponsored by Swiss Tropical and Public Health Institute. Primary endpoint: Length of time between artificial challenge and development of blood stage parasitaemia at 1 month. Started Mar 2004; status: completed.
02
Drugs
PfCS102
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT01031524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01031524.